DDInter259 DDInter1658
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Cabazitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Cabazitaxel {u} (Compound) treats {v} (Disease) prostate cancer
Cabazitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Cabazitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Cabazitaxel {u} (Compound) causes {v} (Side Effect) Cardiac failure
Cabazitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cabazitaxel (Compound) resembles Docetaxel (Compound)
Cabazitaxel (Compound) treats prostate cancer (Disease)
Cabazitaxel (Compound) binds CYP3A5 (Gene)
Cabazitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Cabazitaxel (Compound) causes Cardiac failure (Side Effect)
Cabazitaxel may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Cabazitaxel may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cabazitaxel may lead to a major life threatening interaction when taken with Clozapine